SCYNEXIS Presents Promising Data on SCY-247 Against Drug-Resistant Fungal Infections at TIMM-12 Congress

SCYNEXIS查看公司主页, Inc. announced multiple presentations highlighting data on its second-generation fungerp drug candidate, SCY-247查看药品详情, at the 12th Congress on Trends in Medical Mycology (TIMM-12) taking place September 19-22, 2025, in Bilbao, Spain. The six presentations demonstrate SCY-247's potential to address critical unmet needs in treating drug-resistant fungal infections, particularly Candida auris (搜索)搜索该疾病, which has emerged as a global health threat.

Breakthrough Activity Against Drug-Resistant C. auris

The most significant presentation will feature an oral session demonstrating SCY-247查看药品详情's in vitro activity against C. auris strains, including isolates with mutations commonly associated with echinocandin resistance. The study tested SCY-247 against 65 unique FKS1 (搜索)搜索该靶点-resistant C. auris isolates representing all five known clades (I, II, III, IV, and V). According to the research, SCY-247 consistently demonstrated lower minimum inhibitory concentrations (MICs) compared to echinocandins anidulafungin查看药品详情 and micafungin查看药品详情 against isolates with commonly found FKS1 resistance mutations.

"Our six presentations at this year's TIMM-12 Congress highlight the significant potential of SCY-247查看药品详情 to combat difficult, resistant Candida infections, including C. auris," said David Angulo, M.D., President and Chief Executive Officer of SCYNEXIS查看公司主页. "We are developing SCY-247 to specifically address one of the most serious and challenging issues in infectious disease, and the data from these presentations provide highly encouraging evidence that SCY-247 has the potential to address these difficult-to-treat and life-threatening fungal infections."

Addressing the Growing C. auris Crisis

The urgency of developing new antifungal treatments is underscored by alarming epidemiological trends. C. auris is recognized as a global health threat by both the CDC and WHO, with the fungus exhibiting a 200% increase in incidence in the U.S. from 2019 to 2023. The New York-New Jersey metropolitan area remains a particular hotbed for multidrug- and pandrug-resistant C. auris strains.

In one study, researchers tested 300 C. auris isolates, mostly from the New York area, against SCY-247查看药品详情 and 10 other antifungal agents. The results showed that SCY-247 demonstrated potent activity against C. auris, including pandrug-resistant isolates that have proven challenging for existing therapies.

Broad-Spectrum Antifungal Activity

Beyond C. auris, the presentations will highlight SCY-247查看药品详情's activity against other problematic fungal pathogens. Research on Candida glabrata (搜索)搜索该疾病, a major cause of invasive candidiasis (搜索)搜索该疾病 and WHO high-priority pathogen, showed that SCY-247 maintained in vitro activity against 29 echinocandin-resistant clinical strains. The compound also demonstrated in vivo efficacy in an invasive candidiasis mouse model caused by an echinocandin- and fluconazole查看药品详情-resistant C. glabrata strain.

Additional data will show SCY-247查看药品详情's uniform activity against Candida species with no indication of cross-resistance to echinocandins, based on three months of EUCAST MIC testing of 293 Candida isolates. The compound also exhibited activity against cryptic Aspergillus (搜索)搜索该疾病 species, showing low minimum effective concentrations (MECs) against 48 clinical isolates.

Promising In Vivo Efficacy Data

Animal model studies provide encouraging evidence of SCY-247查看药品详情's therapeutic potential. In a murine model of C. auris infection, seven days of once or twice daily oral SCY-247 treatment resulted in significant reductions in kidney fungal burden in a dose-dependent fashion. Notably, similar activity was observed between once-daily (QD) and twice-daily (BID) dosing regimens, suggesting potential for convenient dosing schedules.

Clinical Development Timeline

SCYNEXIS查看公司主页 anticipates reporting Phase 1 Single Ascending Dose/Multiple Ascending Dose (SAD/MAD) data for oral SCY-247查看药品详情 in Q3 2025, representing an important milestone in advancing this novel antifungal program. This trial will provide crucial safety and pharmacokinetic data to support further clinical development.

SCY-247查看药品详情 represents the second-generation compound from SCYNEXIS查看公司主页's proprietary fungerp antifungal platform. The first representative of this novel class, ibrexafungerp查看药品详情, has been licensed to GSK查看公司主页 and received FDA approval as BREXAFEMME查看药品详情 for vulvovaginal candidiasis (搜索)搜索该疾病 treatment, with late-stage clinical investigation ongoing for life-threatening invasive fungal infections in hospitalized patients.